Delving into the Latest Updates on Sarcoma(Arpeggio Biosciences) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

GPX4

Mechanism

GPX4 antagonists(glutathione peroxidase 4 antagonists)

Therapeutic Areas

Neoplasms

Active Indication

Sarcoma

Inactive Indication-

Originator Organization

Arpeggio Biosciences, Inc.Startup

Active Organization

Arpeggio Biosciences, Inc.Startup

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of rare subtype.
400 patients will be included in this prospective cohort study; they will be identified in the investigating centers in the context of either routine care or a clinical study protocol.
Retrospective cases of patients (100 cases in total) will be identified in all centers through the GSF/GETO clinical databases already setted up (including the clinical base Conticabase).

Start Date26 Apr 2021

Sponsor / Collaborator

Institut Claudius Regaud

100 Clinical Results associated with Sarcoma(Arpeggio Biosciences)

Login to view more data

100 Translational Medicine associated with Sarcoma(Arpeggio Biosciences)

Login to view more data

100 Patents (Medical) associated with Sarcoma(Arpeggio Biosciences)

Login to view more data

100 Deals associated with Sarcoma(Arpeggio Biosciences)

Login to view more data